Page last updated: 2024-09-04

moxifloxacin and mk-0524

moxifloxacin has been researched along with mk-0524 in 1 studies

Compound Research Comparison

Studies (moxifloxacin)	Trials (moxifloxacin)	Recent Studies (post-2010) (moxifloxacin)	Studies (mk-0524)	Trials (mk-0524)	Recent Studies (post-2010) (mk-0524)
3,157	552	1,690	121	57	71

Protein Interaction Comparison

Protein	Taxonomy	moxifloxacin (IC50)	mk-0524 (IC50)
Prostaglandin D2 receptor	Homo sapiens (human)		0.0007

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Atiee, GJ; Crumley, T; Ebel, D; Johnson-Levonas, AO; Lai, E; Luo, WL; Royalty, J; Wagner, J	1

Trials

1 trial(s) available for moxifloxacin and mk-0524

Article	Year
Single therapeutic and supratherapeutic doses of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, do not prolong the QTcF interval in healthy volunteers. Journal of clinical pharmacology, 2010, Volume: 50, Issue:11 Topics: Adolescent; Adult; Aza Compounds; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Humans; Indoles; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Quinolines; Receptors, Immunologic; Receptors, Prostaglandin; Young Adult	2010

Article

Year

Single therapeutic and supratherapeutic doses of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, do not prolong the QTcF interval in healthy volunteers.

Journal of clinical pharmacology, 2010, Volume: 50, Issue:11

Topics: Adolescent; Adult; Aza Compounds; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Humans; Indoles; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Quinolines; Receptors, Immunologic; Receptors, Prostaglandin; Young Adult

2010